Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 2
2013 6
2014 5
2015 4
2016 3
2017 4
2018 6
2019 4
2020 1
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, Ansah HJ, Escoffre-Barbe M, Turhan A, Rousselot P, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG. Saugues S, et al. Among authors: hermet e. Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284860. Online ahead of print. Haematologica. 2024. PMID: 38695126 Free article.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC). Roy L, et al. Among authors: hermet e. Br J Haematol. 2023 Jan;200(2):175-186. doi: 10.1111/bjh.18486. Epub 2022 Oct 10. Br J Haematol. 2023. PMID: 36214090 Clinical Trial.
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Saugues S, Lambert C, Daguenet E, Ansah HJ, Turhan A, Huguet F, Guerci-Bresler A, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG. Saugues S, et al. Among authors: hermet e. Ann Hematol. 2022 Oct;101(10):2241-2255. doi: 10.1007/s00277-022-04955-z. Epub 2022 Aug 30. Ann Hematol. 2022. PMID: 36040480
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells.
Berger MG, Lebecque B, Tassin T, Dannus LT, Berger J, Soucal M, Guerci A, Cony-Makhoul P, Johnson H, Etienne G, Guyotat D, Gagnieu MC, Pereira B, Saugues S, Tournilhac O, Hermet E, Bourgne C. Berger MG, et al. Among authors: hermet e. Sci Rep. 2021 Mar 17;11(1):6187. doi: 10.1038/s41598-021-85734-0. Sci Rep. 2021. PMID: 33731863 Free PMC article.
Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation.
Bondeelle L, Gras J, Michonneau D, Houdouin V, Hermet E, Blin N, Nicolini F, Michallet M, Dominique S, Huynh A, Leroy S, Socié G, Thabut G, Reynaud-Gaubert M, Tazi A, Bergeron A. Bondeelle L, et al. Among authors: hermet e. Bone Marrow Transplant. 2020 May;55(5):982-986. doi: 10.1038/s41409-019-0636-8. Epub 2019 Aug 14. Bone Marrow Transplant. 2020. PMID: 31413312 No abstract available.
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC). Bidet A, et al. Among authors: hermet e. Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20. Haematologica. 2019. PMID: 30573507 Free PMC article.
[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Yafour N, Couturier MA, Azarnoush S, Girault S, Hermet E, Masouridi Levrat S, Schmidt A, Michallet M, Etancelin P, Guillaume T, Malard F, Sirvent A, Yakoub-Agha I, Poiré X. Yafour N, et al. Among authors: hermet e. Bull Cancer. 2019 Jan;106(1S):S40-S51. doi: 10.1016/j.bulcan.2018.05.018. Epub 2018 Nov 6. Bull Cancer. 2019. PMID: 30409466 Review. French.
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R. Bahashwan S, et al. Among authors: hermet e. Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30370957 Free article. No abstract available.
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE. Heiblig M, et al. Among authors: hermet e. Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5. Exp Hematol. 2018. PMID: 30195076 Free article.
36 results